Pediatric Safety Tests In Juvenile Animals Need Validation, AstraZeneca Says
Executive Summary
FDA should confirm whether using juvenile animals to evaluate pediatric drug safety is more predictive of the clinical experience than current practice, AstraZeneca says in comments on a proposed agency guidance
You may also be interested in...
Preclinical Data May Support Single Study For Pediatric Cancer Drugs – Cmte.
Pediatric efficacy of oncology drugs may be shown through one clinical trial with supportive preclinical data, the Pediatric Subcommittee of FDA's Oncologic Drugs Advisory Committee suggested March 17
Preclinical Data May Support Single Study For Pediatric Cancer Drugs – Cmte.
Pediatric efficacy of oncology drugs may be shown through one clinical trial with supportive preclinical data, the Pediatric Subcommittee of FDA's Oncologic Drugs Advisory Committee suggested March 17
CDER Guidance Agenda 2004: Pregnancy, Pediatric Studies Are Priorities
FDA is planning several new guidances to refine recommendations for drug studies in children and pregnant women during 2004, the Center for Drug Evaluation & Research's guidance agenda for the coming year indicates